Background: Treatment preferences and acceptance of side effects (SEs) may vary among patients with non-small cell lung cancer (NSCLC). This analysis aimed to assess patient preferences and willingness to accept trade-offs for a favorable treatment response among patients with locally advanced or metastatic NSCLC (aNSCLC or mNSCLC). Methods: A cross-sectional online survey of patients with NSCLC was conducted between March and May 2023. Patients were recruited from a US-based NSCLC online community and research panel. Eligibility criteria included ≥18 years, self-reported NSCLC diagnosis for ≥6 months, and being under a physician’s care for NSCLC. Survey questions were informed by a literature review, input from a steering committee, and qualitative interviews. Descriptive statistics were generated and reported in aggregate. Results: Overall, 133 patients reported having aNSCLC or mNSCLC and of these, 85 reported having received targeted therapy (Table 1). When asked about the importance of NSCLC treatment attributes, this cohort ranked extension of life, impact on quality of life (QoL), and duration of response as their top priorities. When asked to think about “trade-offs” for a hypothetical new NSCLC treatment with a favorable response, 70% (n=93) reported they were either likely or highly likely to accept a high chance of an SE that requires inpatient management. Additionally, 82% (n=109) reported they were either likely or highly likely to accept a new treatment that may require other treatments to control or manage SEs of this new treatment to achieve a favorable response. When patients were asked about how likely they were to accept different types of SEs for a new NSCLC treatment with a favorable response, 92% (n=122) reported that they were likely or highly likely to accept SEs that were not life-threatening, such as hair loss, skin peeling, and nail disorders. Meanwhile, 44% (n=59) reported that they were likely or highly likely to accept a rare SE that could be life-threatening (e.g., stroke) or cause a serious problem (e.g., blindness). Patients with aNSCLC or mNSCLC who reported receiving targeted therapy at some point (n=85) indicated a similar willingness for SE trade-offs. Conclusions: Patients with aNSCLC or mNSCLC prioritize treatment efficacy and QoL, and a high proportion of patients reported willingness to accept trade-offs for better efficacy with a new treatment.
HSR25-153: Table 1. Patient Demographics
